About Us
About
Ensysce
Ensysce Biosciences has 2 missions.
We are using first in class chemical approaches to treat the severest of pains in a safer way.
We are developing a first in class neuroplastogenic approach to treat CRPS.
Our Philosophy
We focus on innovative chemistry to solve problems with conventional opioid approaches.
We use leading edge technologies to “switch on” and “switch off” opioid release, which delivers a safer drug delivery. We are also the first company to develop a chronic pain therapy targeting the 5-HT2A serotonin receptor using a proprietary, naturally derived compound.
The industry
and Us
“Our technology can change people’s lives. Our TAAP, MPAR and
neuroplastogenic approaches could solve some of the most intractable issues in pain therapy”
D. Lynn Kirkpatrick, PhD
Chief Executive Officer“We know our approaches cannot only provide advances in pain medicine but they also benefit our society. Our team is inspired by this combined mission.”
Dave Humphrey
Chief Financial Officer“We target the toughest diseases where suffering is high and abuse or overdose can be an issue. Our mission is simple, reduce suffering using advanced technologies”
Geoff Birkett
Chief Commercial Officer“We can’t stop severe and chronic pain, but the Ensysce team are committed to helping manage it safely, using advanced chemistry”
Linda Pestano, PhD
Chief Development Officer“Being able to protect against opioid overdose – using MPAR technology – is a disruptive technology that will set Ensysce apart from all other conventional and abuse-deterrent opioid products!”